CurrentcareoregonPolicy N/A

Takhzyro (lanadelumab-flyo) prior authorization

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Prior authorization requirements for initiation and reauthorization of Takhzyro (lanadelumab-flyo) for treatment of hereditary angioedema (HAE) for CareOregon members.

Policy Summary

Payercareoregon

PolicyTakhzyro (lanadelumab-flyo) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and submit medical records documenting confirmed HAE diagnosis, dosing rationale, and either >6 months attack-free or ≥50% reduction in attacks for reauthorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsapproval length

300mg q4wextended dosing

≥50%attack reduction

>6 moattack-free interval

Coverage criteria for Takhzyro (lanadelumab-flyo)

Policy Summary

Payercareoregon

PolicyTakhzyro (lanadelumab-flyo) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentcareoregonPolicy N/A

Takhzyro (lanadelumab-flyo) prior authorization

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Prior authorization requirements for initiation and reauthorization of Takhzyro (lanadelumab-flyo) for treatment of hereditary angioedema (HAE) for CareOregon members.

Policy Summary

Payercareoregon

PolicyTakhzyro (lanadelumab-flyo) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsapproval length

300mg q4wextended dosing

≥50%attack reduction

>6 moattack-free interval

Coverage criteria for Takhzyro (lanadelumab-flyo)

Policy Summary

Payercareoregon

PolicyTakhzyro (lanadelumab-flyo) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

SourceLink

On This Page

Initial Therapy — Initial Authorization

Covered when ALL of the following are met

Diagnosis of hereditary angioedema (HAE) confirmed by genetic testing OR normal C1q with levels below the lab's normal reference range for both C4 and C1INH

Dosing interval rationale: Request is for the extended dosing interval of 300 mg every 4 weeks OR submission of medical records (e.g., chart notes) documenting clinical rationale for keeping the dosing interval at every 2 weeks

Attack severity: History of attacks considered severe with swelling of the face, throat, or gastrointestinal tract that significantly interrupts usual daily activity despite short-term symptomatic treatment

Trigger evaluation: Patient has been evaluated for triggers of HAE attacks and is maximally managed for avoidance of those triggers (e.g., stress, hormonal changes, dental surgery, trauma, medications including ACE inhibitors and estrogen)

Acute therapy not an option: Treatment with acute, abortive therapy (e.g., Firazyr, Berinert) is NOT an option for the patient

Reauthorization

Covered when ONE of the following is met

Attack-free criterion: Patient has been attack free for greater than 6 months>6 months

Clinical improvement criterion: Submission of medical records (e.g., chart notes) demonstrating at least a 50% reduction in the number of angioedema attacks, significant improvement in attack severity, and clinical documentation of functional improvement>=50% reduction

None explicitly listed.

Requests are not medically necessary when the diagnosis of hereditary angioedema (HAE) is not confirmed by genetic testing or by laboratory evidence (normal C1q with both C4 and C1INH below the lab's reference range), or when the member can be adequately managed with acute/abortive therapy. The policy requires documentation that acute/abortive therapies (for example, Firazyr or Berinert) are not an option for the patient before approval of long‑term prophylaxis with lanadelumab.

Key numeric thresholds and coding-relevant criteria

Attack reduction for reauthorization

Reauthorization thresholdAt least a 50% reduction in the number of angioedema attacks compared with baseline

Required documentationSubmission of medical records (e.g., chart notes) demonstrating the ≥50% reduction, improvement in attack severity, and clinical documentation of functional improvement

Applicable therapy stageReauthorization for Takhzyro (lanadelumab-flyo)

Attack-free interval for reauthorization

Reauthorization criterion> 6 months attack-free (patient has been attack free for greater than 6 months)

Documentation to submitMedical records or chart notes confirming the attack-free interval

Applicable therapy stageReauthorization for Takhzyro (lanadelumab-flyo)

Provider requirements and operational notes

Prior Authorization

Prior authorization required; approvals issued for 6 months

Prior authorization is required for both initial requests and reauthorization of Takhzyro. When approved, authorizations are granted for 6 months.

Documentation Required

Confirm acute/abortive therapy is not an option

Document that treatment with acute, abortive therapy (for example, Firazyr or Berinert) is NOT an option for the patient as part of the approval requirements.

Documentation Required

Submit supporting medical records and dosing rationale

Submit medical records (e.g., chart notes) that support the request, including clinical rationale for the chosen dosing interval, confirmation of HAE diagnosis, history of severe attacks, evaluation and management of triggers, and for reauthorization either an attack‑free interval >6 months or documentation of ≥50% reduction in attacks with functional improvement.

Rationale for extended dosing interval (300 mg every 4 weeks) or reason to remain at every 2 weeks
Documentation confirming diagnosis (genetic testing or normal C1q with low C4 and C1INH)
History of severe attacks and trigger evaluation/management
For reauthorization: >6 months attack‑free OR ≥50% reduction in attacks with clinical/functional improvement

Denial Risk

Denial risk if HAE diagnosis or required documentation is lacking

Denial may be triggered if the diagnosis of hereditary angioedema is not confirmed by genetic testing or by laboratory evidence (normal C1q with C4 and C1INH below the lab's reference range), or if required documentation of severe attacks, trigger evaluation/management, or that acute/abortive therapy is not an option is missing.

Key definitions used in the policy

Confirmed HAE

DefinitionDiagnosis confirmed by genetic testing

Alternate laboratory confirmationNormal C1q with both C4 and C1INH below the laboratory's normal reference range

Use in criteriaRequired for initial authorization of lanadelumab (Takhzyro)

Severe HAE attacks

Core definitionSwelling of the face, throat, or gastrointestinal tract that significantly interrupts usual daily activity despite short-term symptomatic treatment

RelevanceRequired as part of initial authorization criteria for Takhzyro

Clinical implicationIndicates severe attacks that may warrant long-term prophylaxis

Clinical background

Hereditary angioedema (HAE) is a genetic disorder characterized by recurrent episodes of non‑pitting, subcutaneous or submucosal swelling that can affect the face, upper airway (throat), and gastrointestinal tract. Attacks involving the throat can threaten the airway, and gastrointestinal attacks commonly cause severe abdominal pain and disruption of usual daily activities. Long‑term prophylaxis with lanadelumab (Takhzyro) is used to reduce attack frequency in patients with confirmed HAE who experience severe attacks or who have inadequate control despite management of triggers and consideration of acute therapies.